Skip to main content
. 2021 Jul 28;9:tkab016. doi: 10.1093/burnst/tkab016

Table 2.

Improvement of UNC4P and VSS scores of hypertrophic scar patients after AFCL and AFCL+PRP treatments

AFCL AFCL+PRP
Pre-treatment First month Third month Sixth month Pre-treatment First month Third month Sixth month
UNC4P 7.68 ± 1.17 6.84 ± 1.27a 5.95 ± 0.55a 4.63 ± 1.09a 8.26 ± 1.22 6.52 ± 1.16b 4.68 ± 1.28b,c 2.61 ± 1.29b,c
 Pliability 1.89 ± 0.31 1.89 ± 0.31 1.89 ± 0.31 1.68 ± 0.46a 2.00 ± 0.25 2.00 ± 0.25 1.90 ± 0.30 1.19 ± 0.40b,c
 Pruritus 2.00 ± 0.46 1.58 ± 0.59a 1.05 ± 0.51a 0.74 ± 0.44a 2.13 ± 0.55 1.23 ± 0.49b,c 0.55 ± 0.56b,c 0.16 ± 0.37b,c
 Pain 1.95 ± 0.60 1.53 ± 0.60a 1.21 ± 0.41a 1.00 ± 0.32a 2.06 ± 0.62 1.45 ± 0.50 0.90 ± 0.47b,c 0.45 ± 0.50b,c
 Paraesthesia 1.84 ± 0.49 1.84 ± 0.49 1.74 ± 0.55 1.21 ± 0.61a 2.06 ± 0.44 1.84 ± 0.51 1.32 ± 0.47b,c 0.80 ± 0.59b,c
VSS 10.89 ± 1.65 10.68 ± 1.66 9.89 ± 1.62a 8.16 ± 1.93a 11.74 ± 1.61 10.39 ± 1.31 8.45 ± 1.04b,c 6.06 ± 1.44b,c
 Pigmentation 2.89 ± 0.45 3.00 ± 0 3.00 ± 0 2.68 ± 0.73 3.00 ± 0 3.00 ± 0 2.87 ± 0.49 2.16 ± 0.99b
 Vascularity 3.21 ± 0.77 2.89 ± 0.97 2.37 ± 0.98a 1.79 ± 0.69a 3.61 ± 0.94 2.58 ± 0.84b 1.77 ± 0.61b,c 1.06 ± 0.35b,c
 Height 2.00 ± 0.32 2.10 ± 0.45 2.16 ± 0.49 2.11 ± 0.55 2.19 ± 0.47 2.23 ± 0.49 1.87 ± 0.49b 1.68 ± 0.47b,c
 Pliability 2.79 ± 0.61 2.68 ± 0.65 2.37 ± 0.48a 1.58 ± 0.59a 2.94 ± 0.50 2.58 ± 0.55b 1.94 ± 0.35b,c 1.16 ± 0.37b,c

UNC4P University of North Carolina 4P Scar Scale, VSS Vancouver Scar Scale, AFCL ablative fractional CO2 laser, PRP platelet-rich plasma

a p < 0.05 compared with pre-treatment value in AFCL group

b p < 0.05 compared with pre-treatment value in AFCL+PRP group

c p < 0.05 compared with the value of the AFCL group at the same time point